BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM
September 17, 2024 7:00 AM EDTEversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes
With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGMs for minimal life disruption
Launch expected early in the fourth quarter of 2024
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose... More
